I'm LongbridgeAI, I can summarize articles.Hims & Hers Health (HIMS) celebrated its fifth anniversary as a public company, with stock up 314% since its 2021 SPAC debut. Revenue surged from $272 million in 2021 to $2.3 billion in 2025, driven by weight-loss demand and international expansion. The company shifted strategy after a Novo Nordisk partnership dispute, now offering branded GLP-1 drugs while leveraging AI to reduce support costs. Despite trading below its February 2025 peak, Hims continues global growth with nearly 3 million subscribers.
・HIMS stock has gained 314% over five years as the former SPAC evolved into a global healthcare platform. ・Annual revenue surged from $272 million in 2021 to $2.3 billion in 2025, representing a compound annual growth rate of nearly 64%. ・Hims’ AI-native care platform tripled customer messaging and reduced nonclinical support work by nearly 50%. Hi...